Abstract: The disclosure provided herein relates generally to mesenchymal-like stem cells “hES-T-MiSC” or “T-MSC” and the method of producing the stem cells. The method comprises culturing embryonic stem cells under conditions that the embryonic stem cells develop through an intermediate differentiation of trophoblasts, and culturing the differentiated trophoblasts to hES-T-MSC or T-MSC, T-MSC derived cells and cell lineages “T-MSC-DL” are also described. Disclosed also herein are solutions and pharmaceutical compositions comprising the T-MSC and/or T-MSC-DL, methods of making the T-MSC and T-MSC-DL, and methods of using the T-MSC and T-MSC-DL for treatment and prevention of diseases, specifically, T-MSC and T-MSC-DL are used as immunosuppressive agents to treat multiple sclerosis and autoimmune diseases.

Abstract: The present invention relates to methods of generating and expanding hitman embryonic stem cell derived mesenchymal-like stem/stromal cells. These hES-MSCs are characterized at least in part by the low level of expression of IL-6. These cells are useful for the prevention and treatment of T cell related autoimmune disease, especially multiple sclerosis, as well as for delivering agents across the blood-brain barrier and the blood-spinal cord barrier. Also provided is a method of selecting clinical grade hES-MSC and a method of modifying MSC to produced a MSC with specific biomarker profile. The modified MSC are useful for treatment of various diseases.

Abstract: The disclosure provided herein relates generally to mesenchymal-like stem cells “hES-T-MiSC” or “T-MSC” and the method of producing the stem cells. The method comprises culturing embryonic stem cells under conditions that the embryonic stem cells develop through an intermediate differentiation of trophoblasts, and culturing the differentiated trophoblasts to hES-T-MSC or T-MSC, T-MSC derived cells and cell lineages “T-MSC-DL” are also described. Disclosed also herein are solutions and pharmaceutical compositions comprising the T-MSC and/or T-MSC-DL, methods of making the T-MSC and T-MSC-DL, and methods of using the T-MSC and T-MSC-DL for treatment and prevention of diseases, specifically, T-MSC and T-MSC-DL are used as immunosuppressive agents to treat multiple sclerosis and autoimmune diseases.

Abstract: The present invention provides a circulating fluidized bed boiler, comprising: furnace side walls; a ceiling; an air distribution plate provided at a bottom of a furnace; and at least one air distribution cone provided on the air distribution plate, wherein each air distribution cone extends upwards from the air distribution plate into an interior of the furnace and has a shape gradually tapered in an extending direction, cone side walls which form the air distribution cone are provided with secondary air ports, the cone side walls are separated from the furnace side walls, and a furnace combustion space is formed and surrounded by the ceiling, the furnace side walls, the air distribution plate, and the cone side walls.

Abstract: The present invention relates to methods of generating and expanding hitman embryonic stem eel! derived mesenchymal-like stem/siromal cells. These hES-MSCs are characterized at least in part by the low level of expression of IL-6. These cells are useful for the prevention and treatment of T cell related autoimmune disease, especially multiple sclerosis, as well as for delivering agents across the blood-brain barrier and the blood-spinal cord barrier. Also provided is a method of selecting clinical grade hES-MSC and a method of modifying MSC to produced a MSC with specific biomarker profile. The modified MSC are useful for treatment of various diseases.

Abstract: The disclosure provided herein relates generally to mesenchymal-like stem cells “hES-T-MiSC” or “T-MSC” and the method of producing the stem cells. The method comprises culturing embryonic stem cells under conditions that the embryonic stem cells develop through an intermediate differentiation of trophoblasts, and culturing the differentiated trophoblasts to hES-T-MSC or T-MSC, T-MSC derived cells and cell lineages “T-MSC-DL” are also described. Disclosed also herein are solutions and pharmaceutical compositions comprising the T-MSC and/or T-MSC-DL, methods of making the T-MSC and T-MSC-DL, and methods of using the T-MSC and T-MSC-DL for treatment and prevention of diseases, specifically, T-MSC and T-MSC-DL are used as immunosuppressive agents to treat multiple sclerosis and autoimmune diseases.

Abstract: Embodiments of the invention provide a water-cooled column formed by side walls connected together to define an enclosed space, each side wall is formed of a water-cooled membrane wall, a working medium is passed through a tube of the water-cooled membrane wall from bottom to top, the water-cooled column comprising: a lower part having a cross section reduced segment, which has a cross section gradually reduced in a direction from bottom to top; and an upper part, wherein the upper part connects with the cross section reduced segment at a connection position, and a cross sectional area of the cross section reduced segment at the connection position is identical to a cross sectional area of the upper part at the connection position. Embodiments of the invention also provide a furnace for defining a reaction space, which comprises a water-cooled column defined as above disposed along a vertical direction therein.

Abstract: A large-size circulating fluidized bed boiler, comprising: a furnace having a vertical furnace center line; and at least two groups of cyclones, each cyclone of each group of cyclones having an inlet gas pass communicated with the furnace. A furnace cross section formed by outer sidewalls and located at the inlet gas pass of the cyclone is a polygon having 2×n sides, and n is a positive integer greater than 1. The polygon is axially symmetric with respect to a perpendicular bisector of each side of the polygon, and when n is 2, the polygon is a square. Triangles formed by two endpoints of an inlet of the inlet gas pass of each cyclone at the cross section and an intersection of the furnace center line and the cross section are congruent. A single flow field in communication with each of the inlet is formed in the cross section.

Abstract: A water-cooled column (4) used in a circulating fluidized bed boiler furnace is disclosed, wherein the water-cooled column is formed by connecting membrane water-cooled walls (41). The water-cooled column (4) includes a lower section (A), an upper section and a transition section. The lower section (A) is a single column and is provided with inner secondary air ports (400) on a side wall thereof. The upper section includes a plurality of sub-columns (B, C). The membrane water-cooled walls at the lower section (A) extend to the upper section through the transition section. Each of the sub-columns (B, C) is formed by connecting extension portions extending upward from respective membrane water-cooled walls (41) in the membrane water-cooled walls (41), which are connected to form the lower section (A), and the plurality of sub-columns (B, C) are separated from each other.

Abstract: Embodiments of the invention provide a water-cooled column formed by side walls connected together to define an enclosed space, each side wall is formed of a water-cooled membrane wall, a working medium is passed through a tube of the water-cooled membrane wall from bottom to top, the water-cooled column comprising: a lower part having a cross section reduced segment, which has a cross section gradually reduced in a direction from bottom to top; and an upper part, wherein the upper part connects with the cross section reduced segment at a connection position, and a cross sectional area of the cross section reduced segment at the connection position is identical to a cross sectional area of the upper part at the connection position. Embodiments of the invention also provide a furnace for defining a reaction space, which comprises a water-cooled column defined as above disposed along a vertical direction therein.

Abstract: The present invention relates to methods of generating and expanding hitman embryonic stem eel! derived mesenchymal-like stem/siromal cells. These hES-MSCs are characterized at least in part by the low level of expression of IL-6. These cells are useful for the prevention and treatment of T cell related autoimmune disease, especially multiple sclerosis, as well as for delivering agents across the blood-brain barrier and the blood-spinal cord barrier. Also provided is a method of selecting clinical grade hES-MSC and a method of modifying MSC to produced a MSC with specific biomarker profile. The modified MSC are useful for treatment of various diseases.

Abstract: The disclosure provided herein relates generally to mesenchymal-like stem cells “hES-T-MiSC” or “T-MSC” and the method of producing the stem cells. The method comprises culturing embryonic stem cells under conditions that the embryonic stem cells develop through an intermediate differentiation of trophoblasts, and culturing the differentiated trophoblasts to hES-T-MSC or T-MSC, T-MSC derived cells and cell lineages “T-MSC-DL” are also described. Disclosed also herein are solutions and pharmaceutical compositions comprising the T-MSC and/or T-MSC-DL, methods of making the T-MSC and T-MSC-DL, and methods of using the T-MSC and T-MSC-DL for treatment and prevention of diseases, specifically, T-MSC and T-MSC-DL are used as immunosuppressive agents to treat multiple sclerosis and autoimmune diseases.

Abstract: The present invention provides a circulating fluidized bed boiler, comprising: furnace side walls; a ceiling; an air distribution plate provided at a bottom of a furnace; and at least one air distribution cone provided on the air distribution plate, wherein each air distribution cone extends upwards from the air distribution plate into an interior of the furnace and has a shape gradually tapered in an extending direction, cone side walls which form the air distribution cone are provided with secondary air ports, the cone side walls are separated from the furnace side walls, and a furnace combustion space is formed and surrounded by the ceiling, the furnace side walls, the air distribution plate, and the cone side walls.

Abstract: A large-size circulating fluidized bed boiler, comprising: a furnace having a vertical furnace center line; and at least two groups of cyclones, each cyclone of each group of cyclones having an inlet gas pass communicated with the furnace. A furnace cross section formed by outer sidewalls and located at the inlet gas pass of the cyclone is a polygon having 2×n sides, and n is a positive integer greater than 1. The polygon is axially symmetric with respect to a perpendicular bisector of each side of the polygon, and when n is 2, the polygon is a square. Triangles formed by two endpoints of an inlet of the inlet gas pass of each cyclone at the cross section and an intersection of the furnace center line and the cross section are congruent. A single flow field in communication with each of the inlet is formed in the cross section.

Abstract: A means and method for treating malaria, schistosomiasis, and cancer using a spiro or dispiro 1,2,4-trioxolane is described. The preferred 1,2,4-trioxolanes include a spiroadamantane group on one side of the trioxolane group, and a spirocyclohexyl on the other side of the trioxolane group. In comparison to artemisinin semisynthetic derivatives, the compounds of this invention are structurally simple, easy to synthesize, non-toxic, and potent against malarial parasites. The compounds of the invention unexpectedly provide a single-dose cure for malaria, as well as prophylactic activity against the same. The compounds are also active against schistosomiasis and cancer.

Abstract: A means and method for treating malaria, schistosomiasis, and cancer using a Spiro or dispiro 1,2,4-trioxolane is described. The preferred 1,2,4-trioxolanes include a spiroadamantane group on one side of the trioxolane group, and a spirocyclohexyl on the other side of the trioxolane group, whereby the spirocyclohexyl ring is preferably substituted at the 4-position. In comparison to artemisinin semisynthetic derivatives, the compounds of this invention are structurally simple, easy to synthesize, non-toxic, and potent against malarial parasites.

Abstract: A means and method for treating malaria, schistosomiasis, and cancer using a spiro or dispiro 1,2,4-trioxolane is described. The preferred 1,2,4-trioxolanes include a spiroadamantane group on one side of the trioxolane group, and a spirocyclohexyl on the other side of the trioxolane group. In comparison to artemisinin semisynthetic derivatives, the compounds of this invention are structurally simple, easy to synthesize, non-toxic, and potent against malarial parasites. The compounds of the invention unexpectedly provide a single-dose cure for malaria, as well as prophylactic activity against the same. The compounds are also active against schistosomiasis and cancer.

Abstract: A means and method for treating malaria, schistosomiasis, and cancer using a spiro or dispiro 1,2,4-trioxolane is described. The preferred 1,2,4-trioxolanes include a spiroadamantane group on one side of the trioxolane group, and a spirocyclohexyl on the other side of the trioxolane group, whereby the spirocyclohexyl ring is preferably substituted at the 4-position. In comparison to artemisinin semisynthetic derivatives, the compounds of this invention are structurally simple, easy to synthesize, non-toxic, and potent against malarial parasites.

Abstract: A means and method for treating malaria, schistosomiasis, and cancer using a spiro or dispiro 1,2,4-trioxolane is described. The preferred 1,2,4-trioxolanes include a spiroadamantane group on one side of the trioxolane group, and a spirocyclohexyl on the other side of the trioxolane group, whereby the spirocyclohexyl ring is preferably substituted at the 4-position. In comparison to artemisinin semisynthetic derivatives, the compounds of this invention are structurally simple, easy to synthesize, non-toxic, and potent against malarial parasites.